To investigate consistency in summaries of product characteristics (SmPCs) of generic antimicrobials, we used natural language processing (NLP) to analyze and compare large amounts of text quantifying consistency between original and generic SmPCs. We manually compared each section of generic and original SmPCs for antimicrobials listed in the electronic Medicines Compendium in the United Kingdom, focusing on omissions and additions of clinically significant information (CSI).
Independently, we quantified differences between the original and generic SmPCs using Kachako, a fully automatic NLP platform. Among the 137 antimicrobials listed in the electronic Medicines Compendium, we identified 193 pairs of original and generic antimicrobial SmPCs for the 48 antimicrobials for which generic SmPCs existed. Of these 193 pairs, 157 (81%) were consistent and 36 were inconsistent with the original SmPC. When the cut-off value of RATE (the index of similarity between two SmPCs) was set at 0.860, our NLP system effectively discriminated consistent generic SmPCs with a specificity of 100% and a sensitivity of 61%. We observed CSI omissions but not additions in the SmPC subsection related to pharmacokinetic properties. CSI additions but not omissions were found in the subsections dealing with therapeutic indications and fertility, pregnancy and lactation.
Despite regulatory guidance, we observed substantial inconsistencies in the information in the United Kingdom SmPCs for antimicrobials. NLP technology proved to be a useful tool for checking large numbers of SmPCs for consistency.
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| INTRODUCTION
The summary of product characteristics (SmPC) 1,2 -a controlled, standardized format for information about medicines in European Union (EU) member countries that is also called drug labeling-is a fundamental resource for promoting the correct use of medicines. 3 SmPCs should regularly be reviewed and updated as new information emerges, because misleading information in SmPCs can result in avoidable adverse events, unnecessary treatment, and failure to treat. The majority of health care professionals believe that SmPCs include sufficient information to make rational decisions when prescribing or dispensing medicines. Previous studies have shown, however, that drug labeling and SmPCs have omitted core clinical pharmacology information in the United States (USA) 4 and the EU. 5 Information about drug interactions in SmPCs has often been found to be incomplete and outdated 6 or even absent. 7 According to the Quality Review of Documents guidance, 8 all relevant aspects of the content of generic SmPCs should be consistent with the SmPCs of reference medicinal products-the so-called "brand-name" medicines. This is because inconsistent information regarding medicines containing the same active ingredient contributes to confusion and poor prescription decisions. Although similar regulatory requirements are applied to generic medicines in the USA, inconsistency has been reported among bioequivalent medicines, both there 9 and in other countries. 7, 10, 11 To the best of our knowledge, only two original studies 9, 10 have reported labeling inconsistencies regarding the same drug, authorized by the same regulatory agency. Storflor et al 10 Evaluating inconsistencies among SmPCs is, however, time consuming, particularly because SmPCs in the UK contain a higher proportion of safety information than do those in the USA and Japan. 12 An automated, reproducible mechanism using natural language processing (NLP) 13 could expedite the evaluation of SmPCs on a largescale basis. 9, 13 To quantify consistency between generic and original SmPCs, we used Kachako, an automated system for NLP. 14, 15 Because they have a social impact that extends beyond individual patients, 16 we aimed to investigate consistency among the UK SmPCs of generic antimicrobials. The long-term risk of antimicrobial resistance is a major threat to global public health, leading to increased health-care costs, prolonged hospital stays, treatment failure, and excess mortality. 17, 18 Substantial differences in safety information for the same drug have been reported among different regulatory bodies; 7 however, we are unaware of any studies on inconsistencies among drug labels for the same antimicrobial with marketing authorization through the same authority.
To determine inconsistencies between original and generic SmPCs, in this study, we examined omissions or additions of clinically significant information (CSI) in generic SmPCs, compared with original SmPCs. We focused on UK SmPCs for antimicrobials to demonstrate that NLP helps to quantify consistency among SmPCs.
| MATERIALS AND METHODS

| Data sources
The unit of analysis for this study was the SmPC, taken as a whole. It provides details of a medicine and its use for health care professionals.
An SmPC is a legal document approved as part of the marketing authorization of each medicine, but it is not a list of information on a specific group of medicines. One SmPC contains information on only one med- When the information was absent from the original SmPC but present in the generic SmPC and we found comparable information in the corresponding US label, we designated the status as CSI addition (Table S1 ). When the comparable information was absent from the corresponding US label, we designated the difference in the presence of information between the original and generic SmPCs as clinically non-significant. (Table S2 ). The detailed procedures regarding this designation are described in Appendix A1.
| Evaluating the performance of our NLP system
For an independent analytical comparison with the gold standard (ie, our manual review), we quantified consistency among the generic SmPCs using our NLP system based on Kachako. We did this to evaluate the performance of the NLP system to support our semantic analysis 14, 15 . Kachako was designed to thoroughly automate any procedure using services for unstructured information processing. Using Kachako, we calculated RATE, an index of similarity between two documents. When one SmPC was identical to the other, RATE was 1;
when the two SmPCs were completely different, RATE was 0.
Given a pair of documents to compare, we calculated the RATE value by counting the number of the same tokens, normalized by the total number of tokens. Tokens of non-content words were discarded using parts of speech. The number of documents available for this study, <1000, which is extremely small and insufficient to create meaningful vectors (e.g. by word2vec/doc2vec). Moreover, these documents could contain different technical words, because they covered different domains of medicines; this could be detrimental when the data size was not large. Our measure, RATE, is robust for small sample size, and does not require training like supervised machine learning methods, as we show in our results.
To confirm the performance of RATE in recognizing differences between two regulatory documents for the same antimicrobial with the same dosage form and strength, we compared RATE between the original SmPC and corresponding patient information leaflet. We also compared RATE between the original SmPC and the corresponding US label.
| Statistical analysis
We calculated descriptive statistics for the outcome measures. The data are presented as means and standard deviations. To evaluate the performance of RATE, we used a receiver operating characteristic curve 23 and the area under the curve to quantify how well RATE performed in determining consistency between the original and generic SmPCs. We set an optimal cut-off value for the receiver operating characteristic analysis to maximize Youden's index 23 , which is maximum = sensitivity + specificity−1. We used JMP software from SAS Institute Japan Ltd. (Tokyo, Japan), as appropriate.
| RESULTS
We found generic SmPCs available for 48 (35%) active pharma- Table 2 ).
After reviewing the data, we constructed a table with a specific set of CSI for a pair of SmPCs. When we checked whether the generic and original SmPCs had each type of CSI (Table S3) , we
found that the content, number, and section of CSI omissions varied widely among the generic SmPCs. All of the SmPCs had omissions, additions or neither of these; no SmPCs had both omissions and additions (Table S4 ). According to these features of CSI omission and addition, we defined the presence of any CSI omission or addition as an inconsistency. We treated the inconsistency in the same way whether there were single or multiple omissions or additions.
The manual data analysis identified 157 (81%) of the 193 pairs of SmPCs as consistent (identical, the same, or similar) with the original SmPC and 36 (19%) as inconsistent (CSI omissions or additions).
As shown in Table 2 , the 36 pairs of SmPCs comprised 33 antibacterial and three antimycotic SmPCs.
We quantified consistency among the SmPCs using RATE. consistent generic SmPCs, the mean of RATE was significantly lower for similar SmPCs than it was for generic SmPCs that were identical or the same, with no overlap between 99% Cis for these point estimates. The sensitivity cut-off for including all of the consistent generic SmPCs was 0.583, the minimum of RATE for consistent SmPCs. The specificity cut-off for excluding any of the inconsistent SmPCs was 0.858, the maximum of RATE for inconsistent SmPCs (Table 3 ). Figure 1 shows the receiver operating characteristic curve for RATE for consistency of the generic SmPCs. The area under the curve for RATE was 0.903 (standard error = 0.02). The optimal cutoff was 0.761 (Table 4A) . Because of the small sample size, the 95% CI was wide: 29-100, for sensitivity and 31-100 for specificity. The cut-off value for RATE of 0.860 effectively discriminated consistent generic SmPCs and excluded inconsistent ones (specificity of 100%
and sensitivity of 61%, Table 4B ). We could not calculate the 95%
CI for sensitivity and specificity at the cut-off value of 0.860, because the number was 0 for the inconsistent SmPCs with RATE of 0.860 or higher.
We also confirmed the performance of RATE in identifying label. For all pairs, RATE between the original SmPC and the corresponding generic SmPC was higher than that between the SmPC and the corresponding US label as well as RATE between the original SmPC and the corresponding PIL (Figure 2 ).
With regard to the type of inconsistency between the original and generic SmPCs, the frequency of CSI omissions and additions varied depending on the specific antimicrobial ( inconsistencies, whereas all of the four generic phenoxymethylpenicillin SmPCs had additions and none had omissions. We found CSI omissions and additions between generic antimicrobial SmPCs and the SmPCs for the corresponding originals. CSI omissions were more common than were CSI additions, and both were observed in generic antibacterial and antimycotic SmPCs. We could not determine why CSI present in original SmPCs was omitted from generic SmPCs; however, it is easy to imagine that generic companies seek to make their SmPCs more "concise" by avoiding partial overlap of the sections in an SmPC, which are not mutually exclusive or collectively exhaustive. When an adverse event is described in one section, the event might not be touched on or, in contrast, might be explained more extensively in another section. We had not expected CSI additions, because generic manufacturers are not responsible for updating SmPCs. Overall, the inconsistencies revealed in this study may result in important information being overlooked, complications in clinical practice, and increased risk of prescription errors and adverse events. We had supposed that any inconsistencies in the SmPCs of generic antimicrobials would be minimal because these inconsistencies could lead to antimicrobial misuse and public health risks, such as antimicrobial resistance. 24 Storflor et al 10 found that generic labels for 13 of the 17 top-selling medicines in Norway had discrepancies, mainly in the information on side effects. Duke et al 9 reported that 68% of multi-manufacturer medicines in the USA had discrepancies inverse drug reactions in safety labeling and that 77.9% of generic manufacturers produced labels that differed from those of the brand-name medicine. The higher percentages of inconsistencies found in generic labels in these two previous studies compared with those found in our study may have resulted from differences in several factors, including the criteria for identifying inconsistencies, the labeling sections of focus and therapeutic areas of interest. Along with previous studies, the present study has identified substantial inconsistencies among generic SmPCs. These findings point to a challenging issue: harmonization across generic medicines. A number of reasons, such as limited technical, human, and financial resources, may explain these inconsistencies. Legal requirements for generic manufacturers to update their SmPCs as new data become available are impractical: Such companies are unlikely to have the resources of brand-name pharmaceutical companies for conducting post-marketing surveys and data collection. Given these challenges, the existing scheme for updating SmPCs has to undergo fundamental change to achieve harmonization across generic medicines. Such change could be supported by a system capable of monitoring inconsistencies among generic SmPCs on an ongoing basis. 9 Implementing structured, standardized electronic SmPCs will also help to reduce inconsistencies and improve prescribing decisions. 25 We recognize several limitations of the present study. In conclusion, we demonstrated that our NLP system, based on the Kachako platform, helped to quantify consistency among SmPCs and extracted inconsistencies between generic and original SmPCs.
Inconsistencies among SmPCs for the same drug authorized by the same authority indicate that the existing regulatory scheme does not work effectively in terms of achieving consistency across generic SmPCs. However, NLP can address the challenge of checking large numbers of regulatory documents for consistency. Further research on rapidly comparing, correcting, and updating SmPCs should contribute to harmonization among generic SmPCs and, ultimately, to the production of a centralized online drug information and safety resource.
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APPENDIX A1
In this section, we describe the methods we used to designate the omission and addition of clinically significant information (CSI) and of clinically non-significant information. We did this according to the presence or absence of this information in the original summary of product characteristics (SmPC), the generic SmPC, and the corresponding US label, and we used the UK SmPC in the absence of a corresponding US label.
To 
| Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX (azithromycin) and other antibacterial drugs, ZITHROMAX (azithromycin)
should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Development of drug-resistant bacteria
Prescribing ZITHROMAX in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
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